BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9261526)

  • 41. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells.
    Goto S; Iida T; Cho S; Oka M; Kohno S; Kondo T
    Free Radic Res; 1999 Dec; 31(6):549-58. PubMed ID: 10630679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
    De Lena M; Lorusso V; Bottalico C; Brandi M; De Mitrio A; Catino A; Guida M; Latorre A; Leone B; Vallejo C; Gargano G
    J Clin Oncol; 1997 Oct; 15(10):3208-13. PubMed ID: 9336357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy.
    Dranitsaris G; Leung P; Ciotti R; Ortega A; Spinthouri M; Liaropoulos L; Labianca R; Quadri A
    Pharmacoeconomics; 2001; 19(9):955-67. PubMed ID: 11700782
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiemetic efficacy of granisetron: a randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy.
    Uchida K; Akaza H; Hattori K; Noguchi R; Kondo F; Ishikawa S; Ohtani M; Hinotsu S; Koiso K
    Jpn J Clin Oncol; 1999 Feb; 29(2):87-91. PubMed ID: 10089949
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells.
    Scambia G; Della Bitta R; Benedetti Panici P; De Vincenzo R; Contu G; Ercoli A; Bonanno G; Pierelli L; Mancuso S
    Gynecol Oncol; 1995 Apr; 57(1):16-22. PubMed ID: 7705696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protective Role of Selenium and High Dose Vitamin E against Cisplatin - Induced Nephrotoxicty in Rats.
    Aksoy A; Karaoglu A; Akpolat N; Naziroglu M; Ozturk T; Karagoz ZK
    Asian Pac J Cancer Prev; 2015; 16(16):6877-82. PubMed ID: 26514460
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantification of sodium thiosulphate protection on cisplatin-induced toxicities.
    Leitao DJ; Blakley BW
    J Otolaryngol; 2003 Jun; 32(3):146-50. PubMed ID: 12921131
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I trial of cisplatin in combination with glutathione.
    Plaxe S; Freddo J; Kim S; Kirmani S; McClay E; Christen R; Braly P; Howell S
    Gynecol Oncol; 1994 Oct; 55(1):82-6. PubMed ID: 7959273
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Experimental studies of the protective effect of deferoxamine mesilate on cisplatin induced toxicity].
    Watanabe H; Kanno H
    Nihon Jibiinkoka Gakkai Kaiho; 1998 Aug; 101(8):967-78. PubMed ID: 9778942
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: effect of 2-amino-4-methylpyridine.
    Saad SY; Najjar TA; Daba MH; Al-Rikabi AC
    Chemotherapy; 2002; 48(6):309-15. PubMed ID: 12673106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical usefulness of ondansetron injection in patients receiving cancer chemotherapy].
    Furue H; Ikeda M; Tsukagoshi S; Taguchi T; Fujii T; Rikimaru T
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):261-71. PubMed ID: 11865633
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.
    Brotto L; Brundage M; Hoskins P; Vergote I; Cervantes A; Casado HA; Poveda A; Eisenhauer E; Tu D; ; ;
    Support Care Cancer; 2016 Mar; 24(3):1241-9. PubMed ID: 26304156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
    Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
    Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized comparative study of antiemetic prophylaxis with ondansentron in a single 32-mg loading dose versus 8 mg every 6 h in patients undergoing cisplatin-based chemotherapy.
    Tsavaris N; Fountzilas G; Mylonakis N; Athanassiadis A; Kosmas C; Karakousis C; Bacoyiannis C; Kosmidis P
    Oncology; 1998; 55(6):513-6. PubMed ID: 9778615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.